Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children.
Wintergerst
U
U
Department of Infectious Diseases and Immunology, Children's Hospital of the Ludwig-Maximilians University, Munich, Germany.
Engelhorn
C
C
Kurowski
M
M
Hoffmann
F
F
Notheis
G
G
Belohradsky
B H
BH
D000293:Adolescent; D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D048588:Benzoxazines; D002219:Carbamates; D002648:Child; D002675:Child, Preschool; D003521:Cyclopropanes; D020008:Delavirdine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D010078:Oxazines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013449:Sulfonamides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013997:Time Factors
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D002219:Carbamates; D003521:Cyclopropanes; D005663:Furans; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; C095108:amprenavir; D020008:Delavirdine; C098320:efavirenz